Importance: Early recognition of adverse events after cardiac surgery is vital for treatment. However, the widely used Society of Thoracic Surgery (STS) risk model has modest performance in predicting adverse events and only applies <80% of cardiac surgeries.

Objective: To develop and validate machine learning (ML) models for predicting outcomes after cardiac surgery.

Design Setting And Participants: ML models, referred as Roux-MMC model, were developed and validated using a retrospective cohort extracted from the STS Adult Cardiac Surgery Database (ACSD) at Maine Medical Center (MMC) between January 2012 to December 2021. It was further validated on a prospective cohort of MMC between January 2022 to February 2024. The performance of Roux-MMC model is compared with the STS model. cardiac surgery.

Main Outcomes And Measures: Postoperative outcomes: mortality, stroke, renal failure, reoperation, prolonged ventilation, major morbidity or mortality, prolonged length of stay (PLOS) and short length of stay (SLOS). Primary measure: area under the receiver-operating curve (AUROC).

Results: A retrospective cohort of 9,841 patients (median [IQR] age, 67 [59-74] years; 7,127 [72%] males) and a prospective cohort of 2,305 patients (median [IQR] age, 67 [59-73] years; 1,707 [74%] males) were included. In the prospective cohort, the Roux-MMC model achieves performance for prolonged ventilation (AUROC 0.911 [95% CI, 0.887-0.935]), PLOS (AUROC 0.875 [95% CI, 0.848-0.898]), renal failure (AUROC 0.878 [95% CI, 0.829-0.921]), mortality (AUROC 0.882 [95% CI, 0.837-0.920]), reoperation (AUROC 0.824 [95% CI, 0.787-0.860]), SLOS (AUROC 0.818 [95% CI, 0.801-0.835]) and major morbidity or mortality (AUROC 0.859 [95% CI, 0.832-0.884]). The Roux-MMC model outperforms the STS model for all 8 outcomes, achieving 0.020-0.167 greater AUROC. The Roux-MMC model covers all cardiac surgery patients, while the STS model applies to only 65% in the retrospective and 77% in the prospective cohorts.

Conclusion And Relevance: We developed ML models to predict 8 postoperative outcomes on all cardiac surgery patients using preoperative and intraoperative variables. The Roux-MMC model outperforms the STS model in the prospective cohort. The Roux-MMC model is built on STS ACSD, a data system used in ∼1000 US hospitals, thus, it has the potential to easily applied in other hospitals.

Key Points: . Can a predictive model be developed using preoperative and intraoperative variables from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) to accurately predict adverse events after cardiac surgery? Machine learning (ML) models developed and validated on a retrospective cohort of 9,841 patients. In the prospective validation cohort, models demonstrated good discrimination for postoperative adverse events including mortality (AUC, 0.882), prolonged ventilation (AUC, 0.911), renal failure (AUC, 0.878), major morbidity or mortality (AUC, 0.859) and prolonged length of stay (AUC, 0.875). ML Models outperform the widely used STS model. . Predictive models based on preoperative and intraoperative variables from STS ACSD, a data collection system implemented in ∼1000 US hospitals, were developed and validated to predict adverse events after cardiac surgery, allowing for straightforward testing at other institutions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888533PMC
http://dx.doi.org/10.1101/2025.02.24.25322811DOI Listing

Publication Analysis

Top Keywords

adverse events
12
events cardiac
8
cardiac surgery
8
development validation
4
validation machine
4
machine learning
4
learning models
4
models adverse
4
surgery early
4
early recognition
4

Similar Publications

Background: Amyotrophic lateral sclerosis (ALS) leads to rapid physiological and functional decline before causing untimely death. Current best-practice approaches to interdisciplinary care are unable to provide adequate monitoring of patients' health. Passive in-home sensor systems enable 24×7 health monitoring.

View Article and Find Full Text PDF

Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual care arm) versus fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 men (18- 40 years) with at least three episodes of SCA-related priapism in the past 12 months.

View Article and Find Full Text PDF

Background: Congenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified.

View Article and Find Full Text PDF

This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.

View Article and Find Full Text PDF

Background: Hospital studies suggest that scrub typhus is a leading cause of severe undifferentiated fever in regions across Asia where the disease is endemic, but the population-based incidence of infection and illness has been little studied.

Methods: We conducted a population-based cohort study to assess epidemiologic and clinical characteristics of scrub typhus in 37 villages in Tamil Nadu, India, where the disease is highly endemic. Study participants were visited every 6 to 8 weeks over a period of 2 years; a venous blood sample was obtained from those who had had fever since the last visit.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!